Drugs / Lopinavir/ritonavir
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT01700790 | Feb 2016 → Nov 2018 | AIDS, tuberculosis | University of Miami | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lopinavir/ritonavir | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01700790 ↗ |
| Known as | LPV/r | “To overcome the reduction in serum concentrations of lopinavir/ritonavir (LPV/r) when used in combination with rifampicin, 800/200 mg or 400/400 mg doses are used.” PMID 31704214 ↗ Nov 2019 |